Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp., a Delaware corporation and emerging growth company, on April 25, 2025, covering events occurring on April 23, 2025. The filing primarily addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it notes that the independent auditor's reports for the fiscal years ended December 31, 2024, and December 31, 2023, included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Change in Auditor: The Company dismissed Marcum LLP as its independent registered public accounting firm effective April 23, 2025.
- New Engagement: CBIZ CPAs P.C. was engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Reason for Change: CBIZ acquired the attest business of Marcum LLP effective November 1, 2024. Marcum continued to serve the Company until the formal transition on April 23, 2025.
- Audit History: No disagreements or reportable events occurred between the Company and Marcum during the fiscal years 2023 and 2024, except for a material weakness related to the review of the annual income tax provision for 2023, which was remediated as of December 31, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the previously disclosed going concern uncertainty. The transition of the audit firm was approved by the Audit Committee of the Board of Directors.
Investor Verification Checklist
- Verify the status of the "substantial doubt about going concern" noted in the 2023 and 2024 audit reports.
- Confirm the remediation of the material weakness regarding the annual income tax provision identified in the 2023 audit.
- Review the letter from Marcum LLP (Exhibit 16.1) to ensure no undisclosed disagreements exist.
- Monitor upcoming financial filings to assess the Company's liquidity position given the prior going concern warning.